1502 TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation.
https://www.cell.com/cell/fulltext/S0092-8674(21)00382-2
1501 Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States.
https://www.cell.com/cell/fulltext/S0092-8674(21)00383-4
1500 A global metagenomic map of urban microbiomes and antimicrobial resistance.
https://www.cell.com/cell/fulltext/S0092-8674(21)00585-7
1499 The anti-leprosy drug clofazimine inhibits coronavirus replication in several cell models and shows potent antiviral activity against SARS-CoV-2 infection in a hamster model, particularly when used in combination with remdesivir.
https://www.nature.com/articles/s41586-021-03431-4
1498 A variant lineage of SARS-CoV-2 associated with rapid transmission in Manaus, Brazil, evolved in November 2020 with immune escape characteristics.
https://science.sciencemag.org/content/372/6544/815
1497 The circadian clock ensures successful DNA replication in cyanobacteria.
https://www.pnas.org/content/118/20/e2022516118
1496 The stepwise assembly of the neonatal virome is modulated by breastfeeding.
https://www.nature.com/articles/s41586-020-2192-1
1495 RNA-sequencing experiments determine that sorbitol, a metabolite produced by the host enzyme aldose reductase, is exploited by Clostridium difficile in its adaptation to inflammatory conditions in the gut.
https://www.nature.com/articles/s41586-021-03502-6
1494 Analysis of community-tested cases of SARS-CoV-2 indicates that the B.1.1.7 variant is not only more transmissible than pre-existing variants, but may also cause more severe illness, and is associated with a higher risk of death.
https://www.nature.com/articles/s41586-021-03426-1
1493 Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike.
https://www.pnas.org/content/118/19/e2100425118
|
